Vaccinology in the post−COVID-19 era

DOI Web Site 1 Citations
  • Rino Rappuoli
    Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy;
  • Ennio De Gregorio
    Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy;
  • Giuseppe Del Giudice
    Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy;
  • Sanjay Phogat
    Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy;
  • Simone Pecetta
    Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy;
  • Mariagrazia Pizza
    Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy;
  • Emmanuel Hanon
    Research and Development Centre, GlaxoSmithKline (GSK), 1330 Rixensart, Belgium

Description

<jats:p>The COVID-19 pandemic is a shocking reminder of how our world would look in the absence of vaccination. Fortunately, new technologies, the pace of understanding new and existing pathogens, and the increased knowledge of the immune system allow us today to develop vaccines at an unprecedented speed. Some of the vaccine technologies that are fast-tracked by the urgency of COVID-19 may also be the answer for other health priorities, such as antimicrobial resistance, chronic infections, and cancer, that the post-COVID-19 world will urgently need to face. This perspective analyzes the way COVID-19 is transforming vaccinology and the opportunities for vaccines to have an increasingly important role in health and well-being.</jats:p>

Journal

Citations (1)*help

See more

Details 詳細情報について

Report a problem

Back to top